Rheuminations: Infection or RA Flare?MedPage TodayFor the transplant, he was given standard induction immunosuppression, with intravenous methylprednisone and basiliximab being given preoperatively, and oral prednisone, mycophenolate mofetil, and tacro…
Multiple Sclerosis — KOL Insight and Consensus Outlook ModulesSYS-CON Media (press release)Rebif (interferon beta-1a; Merck Serono) forecast2.14.Extavia (interferon beta-1b; Novartis) forecast2.15.Lemtrada (alemtuzumab; Genzyme/Sanofi) forecast2.16.La…
|
2014 Outlook: New Drugs in Hepatitis C, MS, Oncology Are Expected This Year
Atlantic Information Services, Inc. … to approve it (see story, p. 1). Other potential additions, she says, include Teva’s laquinimod, Biogen Idec and Abbott Laboratories’ daclizumab and ocrelizumab from Biogen Idec and Roche. © 2014 by Atlantic Information Services, Inc. All Rights … |
|
Biogen Idec-Aktie: Prall gefüllte Pipeline – Kaufen – Nomura Securties …
AktienCheck Der Fokus von Aktienanalyst M. Ian Somaiya liege für das Börsenjahr 2014 auf den Phase-III MS Daten der USD 2 Mrd.-Chance daclizumab zur Jahresmitte und den anti-LINGO-Phase-II-Daten im vierten Quartal 2014. Aktienanalyst M. Ian Somaiya … |
AbbVie Advances with Cancer Candidate – Analyst BlogNASDAQAbbVie has several pipeline-related events lined up this year including data on multiple sclerosis candidate, daclizumab from the DECIDE study in mid-14 and data on Elagolix from one of the two …
AbbVie Advances with Cancer CandidateZacks.comAbbVie has several pipeline-related events lined up this year including data on multiple sclerosis candidate, daclizumab from the DECIDE study in mid-14 and data on Elagolix from one of the two pivotal stud…
|
Nomura Reiterates Bullish View on Biogen (BIIB) on Tecfidera Sales
StreetInsider.com (subscription) “We remain focused on daclizumab Phase III MS data in mid-2014 given its $2bn revenue opportunity and anti-LINGO Phase II optic neuritis data in 4Q14, given its read through to the MS trial (2015E). In a year of regulatory and commercial execution, we … |
|
Was hat sich 2013 in der MS-Therapie getan? – AMSEL – Multiple Sklerose …
Multiple Sklerose News: Startseite In Phase-III-Studien befinden sich derzeit Daclizumab, Laquinimod, Ocrelizumab, Ofatumumab und auch Rituximab.Für Ofatumumab und Rituximab ergänzte die FDA im September die Produktinformationen um eine Black-Box-Warnung, die auf das Risiko … |
Multiple Sklerose News: Startseite |
Was hat sich 2013 in der MS-Therapie getan?
Multiple Sklerose News: Startseite In Phase-III-Studien befinden sich derzeit Daclizumab, Laquinimod, Ocrelizumab, Ofatumumab und auch Rituximab.Für Ofatumumab und Rituximab ergänzte die FDA im September die Produktinformationen um eine Black-Box-Warnung, die auf das Risiko … |
FDA Turns Down MS Drug LemtradaMedPage TodayHe indicated that biologic agents targeting specific immune cell classes — the anti-CD25 drug daclizumab (Zenepax) and the B-cell depleting agent ocrelizumab — also were promising for MS. Alemtuzumab had pr…